Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

Q4 2024 Earnings Call Transcript March 26, 2025 Dyadic International, Inc. misses on earnings expectations. Reported EPS is $ ...

An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus (RSV) for ...

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., have described a next-generation vaccination technology ...